newsfilter
← Latest News
GlobeNewswire·

LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test

LONDON, Dec. 14, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced it has received $14.2M in grants from the Bill & Melinda Gates